Comparative Efficacy and Safety of Oral P2Y 12 Inhibitors in Acute Coronary Syndrome | Zendy

Eliano Pio Navarese | Zendy; Safi U. Khan | Zendy; Michalina Kołodziejczak | Zendy; Jacek Kubica | Zendy; Sergio Buccheri | Zendy; Christopher P. Can | Zendy; Paul A. Gurbel | Zendy; Stefano De Servi | Zendy; Andrzej Budaj | Zendy; Antonio L. Bartorelli | Zendy; Daniela Trabattoni | Zendy; E. Magnus Ohman | Zendy; Lars Wallentin | Zendy; Matthew T. Roe | Zendy; Stefan James | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Comparative Efficacy and Safety of Oral P2Y ₁₂ Inhibitors in Acute Coronary Syndrome

Author(s) -

Eliano Pio Navarese,

Safi U. Khan,

Michalina Kołodziejczak,

Jacek Kubica,

Sergio Buccheri,

Christopher P. Can,

Paul A. Gurbel,

Stefano De Servi,

Andrzej Budaj,

Antonio L. Bartorelli,

Daniela Trabattoni,

E. Magnus Ohman,

Lars Wallentin,

Matthew T. Roe,

Stefan James

Publication year - 2020

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.120.046786

Subject(s) - medicine , acute coronary syndrome , intensive care medicine , cardiology , myocardial infarction

New randomized, controlled trials have become available on oral P2Y 12 inhibitors in acute coronary syndrome. We aimed to evaluate current evidence comparing the efficacy and safety profile of prasugrel, ticagrelor, and clopidogrel in acute coronary syndrome by a meta-analysis of randomized controlled trials.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research